IDEAS home Printed from https://ideas.repec.org/a/sae/soueco/v4y2003i1p73-98.html
   My bibliography  Save this article

The Corporate Pharmaceutical Model and the Legacy of Doha: Whither a Global Consensus on Public Health Governance?

Author

Listed:
  • Joseph Savirimuthu

    (Liverpool Law School, University of Liverpool, Liverpool L69 7ZS)

Abstract

This paper attempts to demonstrate that the present governance challenges facing policy makers in the WTO and its member states with regard to the public health crises in developing countries cannot be simply overcome by modifying the TRIPs Agreement. One argument pursued in this paper is that any move towards an ex peditious solution must first of all acknowledge the significance of market con straints for the corporate pharmaceutical supply model; and, second, that public health governance policies formulated by governments in both developing and developed countries revolve around the ideological and political preference for market norms and values as operatives of distributive justice. Whilst it is true that TRIPs does constrain the autonomy of governments in developing countries to better manage their public health needs, the paper poses the question as to whether the time is right to rethink the concept of public health and essential medicines in the age of globalization.

Suggested Citation

  • Joseph Savirimuthu, 2003. "The Corporate Pharmaceutical Model and the Legacy of Doha: Whither a Global Consensus on Public Health Governance?," South Asia Economic Journal, Institute of Policy Studies of Sri Lanka, vol. 4(1), pages 73-98, March.
    • Handle: RePEc:sae:soueco:v:4:y:2003:i:1:p:73-98
    DOI: 10.1177/139156140300400106
    as

    Download full text from publisher

    File URL: https://journals.sagepub.com/doi/10.1177/139156140300400106
    Download Restriction: no
    File URL: https://libkey.io/10.1177/139156140300400106?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Lanjouw, J.O., 1997. "The Introduction of Pharmaceutical Product Patents in India: "Heartless Exploitation of the Poor and Suffering"?," Papers 775, Yale - Economic Growth Center.
    2. Abbott, Frederick M, 1998. "The Enduring Enigma of Trips: A Challenge for the World Economic System," Journal of International Economic Law, Oxford University Press, vol. 1(4), pages 497-521, December.
    3. Jayashree Watal, 2000. "Pharmaceutical Patents, Prices and Welfare Losses: Policy Options for India Under the WTO TRIPS Agreement," The World Economy, Wiley Blackwell, vol. 23(5), pages 733-752, May.
    4. Nogues, Julio, 1990. "Patents and pharmaceutical drugs : understanding the pressures on developing countries," Policy Research Working Paper Series 502, The World Bank.
    5. Keith E. Maskus, 2000. "Intellectual Property Rights in the Global Economy," Peterson Institute Press: All Books, Peterson Institute for International Economics, number 99, October.
    6. Oecd, 2002. "Access for Business," OECD Digital Economy Papers 67, OECD Publishing.
    7. Jean O. Lanjouw & Iain Cockburn, 2000. "Do Patents Matter?: Empirical Evidence after GATT," NBER Working Papers 7495, National Bureau of Economic Research, Inc.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Yi Qian, 2010. "Are National Patent Laws the Blossoming Rain?," NBER Working Papers 16295, National Bureau of Economic Research, Inc.
    2. Lee Branstetter & Raymond Fisman & C. Fritz Foley, 2005. "Do Stronger Intellectual Property Rights Increase International Technology Transfer? Empirical Evidence from U.S. Firm-Level Data," NBER Working Papers 11516, National Bureau of Economic Research, Inc.
    3. Bond, Eric W. & Saggi, Kamal, 2014. "Compulsory licensing, price controls, and access to patented foreign products," Journal of Development Economics, Elsevier, vol. 109(C), pages 217-228.
    4. Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
    5. Panle Jia & Pinelopi K. Goldberg & Shubham Chaudhuri, 2006. "Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India," American Economic Review, American Economic Association, vol. 96(5), pages 1477-1514, December.
    6. Chih‐Hai Yang, 2008. "Effects Of Strengthening Intellectual Property Rights In Newly Industrialized Economies: Evidence From Taiwan’S 1994 Patent Reform," Contemporary Economic Policy, Western Economic Association International, vol. 26(2), pages 259-275, April.
    7. Ming Liu & Sumner la Croix, 2013. "A Cross-Country Index of Intellectual Property Rights in Pharmaceutical Innovations," Working Papers 201313, University of Hawaii at Manoa, Department of Economics.
    8. Gamba, Simona, 2017. "The Effect of Intellectual Property Rights on Domestic Innovation in the Pharmaceutical Sector," World Development, Elsevier, vol. 99(C), pages 15-27.
    9. Stremmel, Dennis, 2004. "Geistige Eigentumsrechte im Welthandel: Stellt das TRIPs-Abkommen ein Protektionsinstrument der Industrieländer dar?," University of Göttingen Working Papers in Economics 32, University of Goettingen, Department of Economics.
    10. Carsten Fink, 2001. "Patent Protection, Transnational Corporations, and Market Structure: A Simulation Study of the Indian Pharmaceutical Industry," Journal of Industry, Competition and Trade, Springer, vol. 1(1), pages 101-121, March.
    11. Papageorgiadis, Nikolaos & Cross, Adam R. & Alexiou, Constantinos, 2013. "The impact of the institution of patent protection and enforcement on entry mode strategy: A panel data investigation of U.S. firms," International Business Review, Elsevier, vol. 22(1), pages 278-292.
    12. Mazumdar, Mainak & Banerjee, Dyuti S., 2012. "On price discrimination, parallel trade and the availability of patented drugs in developing countries," International Review of Law and Economics, Elsevier, vol. 32(1), pages 188-195.
    13. Joan-Ramon Borrell & Jayashree Watal, 2002. "Impact of Patents on Access to HIV/AIDS Drugs in Developing Countries," CID Working Papers 92, Center for International Development at Harvard University.
    14. Larry D. Qiu & Huayang Yu, 2010. "Does the Protection of Foreign Intellectual Property Rights Stimulate Innovation in the US?," Review of International Economics, Wiley Blackwell, vol. 18(5), pages 882-895, November.
    15. Calestous Juma and Jayashree Watal, 2001. "Global Governance and Technology," Human Development Occasional Papers (1992-2007) HDOCPA-2001-05, Human Development Report Office (HDRO), United Nations Development Programme (UNDP).
    16. Francesco Laforgia & Fabio Montobbio & Luigi Orsenigo, 2007. "IPRs, technological and industrial development and growth: the case of the pharmaceutical industry," KITeS Working Papers 206, KITeS, Centre for Knowledge, Internationalization and Technology Studies, Universita' Bocconi, Milano, Italy, revised Oct 2007.
    17. Duggan, Mark & Goyal, Aparajita, 2012. "Pharmaceutical patents and prices : a preliminary empirical assessment using data from India," Policy Research Working Paper Series 6063, The World Bank.
    18. repec:wip:wpaper:4 is not listed on IDEAS
    19. Ramesh Govindaraj & Gnanaraj Chellaraj, 2002. "The Indian Pharmaceutical Sector : Issues and Options for Health Sector Reform," World Bank Publications - Books, The World Bank Group, number 15231, December.
    20. Jillian Clare Cohen & Kristina M. Lybecker, 2005. "AIDS Policy and Pharmaceutical Patents: Brazil's Strategy to Safeguard Public Health," The World Economy, Wiley Blackwell, vol. 28(2), pages 211-230, February.
    21. Jean O. Lanjouw, 2003. "Intellectual Property and the Availability of Pharmaceuticals in Poor Countries," NBER Chapters, in: Innovation Policy and the Economy, Volume 3, pages 91-130, National Bureau of Economic Research, Inc.

    More about this item

    Keywords

    (JEL: I18; F13; 034) Keywords: Public Health; Pharmaceuticals; Trade-Related Intellectual Prop erty Rights; Doha Declaration; World Trade Organization.;
    All these keywords.

    JEL classification:

    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
    • F13 - International Economics - - Trade - - - Trade Policy; International Trade Organizations

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:soueco:v:4:y:2003:i:1:p:73-98. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: SAGE Publications (email available below). General contact details of provider: http://www.ips.lk/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.